The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases

por Ramaswamy, Madhu, Tummala, Raj, Streicher, Katie, Nogueira da Costa, Andre, Brohawn, Philip Z.
Publicado 2021

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma

por Cheng, Li, Creasy, Todd, Pilataxi, Fernanda, Greenlees, Lydia, Vence, Luis, Sridhar, Sriram, Streicher, Katie
Publicado 2021

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study

por Levin, Myron J, Ustianowski, Andrew, De Wit, Stéphane, Beavon, Rohini, Thissen, Jesse, Seegobin, Seth, Streicher, Katie, Kiazand, Alexandre, Esser, Mark T
Publicado 2023

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus

por Chia, Yen Lin, Tummala, Raj, Mai, Tu H., Rouse, Tomas, Streicher, Katie, White, Wendy I., Morand, Eric F., Furie, Richard A.
Publicado 2022

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study

por Levin, Myron J, Ustianowski, Andrew, Thissen, Jesse, Seegobin, Seth, Beavon, Rohini, Dey, Kanika, Kelly, Elizabeth J, Near, Karen A, Streicher, Katie, Kiazand, Alexandre, Esser, Mark T
Publicado 2023

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study

por Richard Hobbs, F D, Montgomery, Hugh, Padilla, Francisco, Campos, Jesus Abraham Simón, Arbetter, Douglas, Seegobin, Seth, Kiazand, Alexandre, Streicher, Katie, Martinez-Alier, Nuria, Cohen, Taylor, Esser, Mark T
Publicado 2023

Genomic signatures characterize leukocyte infiltration in myositis muscles

por Zhu, Wei, Streicher, Katie, Shen, Nan, Higgs, Brandon W, Morehouse, Chris, Greenlees, Lydia, Amato, Anthony A, Ranade, Koustubh, Richman, Laura, Fiorentino, David, Jallal, Bahija, Greenberg, Steven A, Yao, Yihong
Publicado 2012

Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma

por Jiang, Liyan, Zhu, Wei, Streicher, Katie, Morehouse, Chris, Brohawn, Philip, Ge, Xiaoxiao, Dong, Zhengwei, Yin, Xiaolu, Zhu, Guanshan, Gu, Yi, Ranade, Koustubh, Higgs, Brandon W, Yao, Yihong, Huang, Jiaqi
Publicado 2014

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants

por Roe, Tiffany L., Brady, Tyler, Schuko, Nicolette, Nguyen, Amy, Beloor, Jagadish, Guest, Johnathan D., Aksyuk, Anastasia A., Tuffy, Kevin M., Zhang, Tianhui, Streicher, Katie, Kelly, Elizabeth J., Kijak, Gustavo H.
Publicado 2023

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

por Vital, Edward M, Merrill, Joan T, Morand, Eric F, Furie, Richard A, Bruce, Ian N, Tanaka, Yoshiya, Manzi, Susan, Kalunian, Kenneth C, Kalyani, Rubana N, Streicher, Katie, Abreu, Gabriel, Tummala, Raj
Publicado 2022

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

por Schiopu, Elena, Chatterjee, Soumya, Hsu, Vivien, Flor, Armando, Cimbora, Daniel, Patra, Kaushik, Yao, Wenliang, Li, Jing, Streicher, Katie, McKeever, Kathleen, White, Barbara, Katz, Eliezer, Drappa, Jorn, Sweeny, Sarah, Herbst, Ronald
Publicado 2016

Altered Expression of Insulin Receptor Isoforms in Breast Cancer

por Huang, Jiaqi, Morehouse, Chris, Streicher, Katie, Higgs, Brandon W., Gao, Jin, Czapiga, Meggan, Boutrin, Anmarie, Zhu, Wei, Brohawn, Philip, Chang, Yong, Viner, Jaye, LaVallee, Theresa, Richman, Laura, Jallal, Bahija, Yao, Yihong
Publicado 2011

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab)...

por Forte-Soto, Pablo, Albayaty, Muna, Brooks, Dennis, Arends, Rosalinda H, Tillinghast, John, Aksyuk, Anastasia A, Bouquet, Jerome, Chen, Cecil, Gebre, Asfiha, Kubiak, Robert J, Pilla Reddy, Venkatesh, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Esser, Mark T
Publicado 2023

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

por Tuffy, Kevin M, Ahani, Bahar, Aksyuk, Anastasia A, Avila, Miles, Brady, Tyler, Kijak, Gustavo H, Koh, Gavin, Levin, Myron J, Roe, Tiffany L, Schuko, Nicolette, Thissen, Jesse, Ustianowski, Andrew, Zhang, Tianhui, Kelly, Elizabeth J, Streicher, Katie
Publicado 2023

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

por Brady, Tyler, Zhang, Tianhui, Tuffy, Kevin M., Haskins, Nantaporn, Du, Qun, Lin, Jia, Kaplan, Gilad, Novick, Steven, Roe, Tiffany L., Ren, Kuishu, Rosenthal, Kim, McTamney, Patrick M., Abram, Michael E., Streicher, Katie, Kelly, Elizabeth J.
Publicado 2022

Development and analytical performance of a new ARCHITECT automated dipeptidyl peptidase-4 immunoassay

por Hemken, Philip M., Jeanblanc, Nicolette M., Rae, Tracey, Brophy, Susan E., Datwyler, Maria J., Xu, Ying, Manetz, T. Scott, Vainshtein, Inna, Liang, Meina, Xiao, Xiaodong, Chowdhury, Partha S., Chang, Chien-ying, Streicher, Katie, Greenlees, Lydia, Ranade, Koustubh, Davis, Gerard J.
Publicado 2017

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

por Hobbs, F. D. Richard, Montgomery, Hugh, Padilla, Francisco, Simón-Campos, Jesus Abraham, Kim, Kenneth, Arbetter, Douglas, Padilla, Kelly W., Reddy, Venkatesh Pilla, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Viani, Rolando M., Johnsson, Eva, Koh, Gavin C. K. W., Esser, Mark T.
Publicado 2023

Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus

por Smith, Michael A., Chiang, Chia-Chien, Zerrouki, Kamelia, Rahman, Saifur, White, Wendy I., Streicher, Katie, Rees, William A., Schiffenbauer, Adam, Rider, Lisa G., Miller, Frederick W., Manna, Zerai, Hasni, Sarfaraz, Kaplan, Mariana J., Siegel, Richard, Sinibaldi, Dominic, Sanjuan, Miguel A., Casey, Kerry A.
Publicado 2020

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

por Tu, Eric, McGlinchey, Kelly, Wang, Jixin, Martin, Philip, Ching, Steven L.K., Floc’h, Nicolas, Kurasawa, James, Starrett, Jacqueline H., Lazdun, Yelena, Wetzel, Leslie, Nuttall, Barrett, Ng, Felicia S.L., Coffman, Karen T., Smith, Paul D., Politi, Katerina, Cooper, Zachary A., Streicher, Katie
Publicado 2022

IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE

por Wang, Shu, Wang, Jingya, Kumar, Varsha, Karnell, Jodi L., Naiman, Brian, Gross, Phillip S., Rahman, Saifur, Zerrouki, Kamelia, Hanna, Richard, Morehouse, Christopher, Holoweckyj, Nicholas, Liu, Hao, Manna, Zerai, Goldbach-Mansky, Raphaela, Hasni, Sarfaraz, Siegel, Richard, Sanjuan, Miguel, Streicher, Katie, Cancro, Michael P., Kolbeck, Roland, Ettinger, Rachel
Publicado 2018